Zoe June Assaf
Senior Director, Cancer Genomics and Emerging Technologies Revolution Medicines
Seminars
Wednesday 4th February 2026
Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints to Enhance Patient Selection & Monitoring
3:15 pm
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?
